FOXM1 and triple-negative breast carcinoma: Park et al. (31) investigated that FOXM1, an oncogenic transcription factor, and putative substrate of MELK, may sensitize resistant triple negative breast cancer cells to doxorubicin treatment by regulating the DNA damage repair genes.